Roche signed a strategic partnership with Nvidia to build an expansive AI computing ecosystem aimed at accelerating drug discovery, diagnostics development, and internal R&D workflows. The plan echoes recent investments by other large drugmakers in high-performance computing and positions Roche to scale large models and generative AI across translational and clinical pipelines. The collaboration will combine Roche’s biomedical datasets and domain expertise with Nvidia’s GPU infrastructure and software stack to run large-scale modeling, simulation, and ML training workloads. Roche framed the move as a competitiveness play to shorten discovery timelines and boost biomarker and diagnostic development throughput. The pact follows a broader industry trend where Big Pharma partners with hyperscale compute vendors to internalize AI capabilities rather than rely solely on external vendors. Executives say the factory approach aims to reduce time to target, improve trial design, and strengthen regulatory evidence generation through advanced simulation and federated learning. Operational details, including deployment timelines, data governance, and regulatory validation paths for AI‑derived outputs, will determine the partnership’s near-term impact on program prioritization and pipeline acceleration.